On this day — March 12
March 12, 1950, in The Star: Walter H. Wellborn of Piedmont Route 1 is in the running for a seat on the Calhoun County Board of Education, a position to which he was appointed around a year ago to fill the unexpired term of a retiring member. A native of Calhoun County, Mr. Wellborn was born in 1901 and has spent most of his life here. He's the son of M. B. Wellborn, former president of the First National Bank of Anniston. Walter Wellborn is a farmer and businessman, an Episcopalian by faith and chairman of the Red Cross drive in Jacksonville. Mr. Wellborn announced his candidacy for the post yesterday. Also on this date: An advertisement for Westinghouse television sets at Anniston Electric Company tries to entice the potential buyer with the promise he'll see Anniston-related sports programming tonight at 7:30. That's when Fred Sington of Birmingham station WAPI will interview Harold Cuyler, the popular young business manager of the Anniston Rams, about Anniston's professional baseball prospects for 1950.
March 12, 2000, in The Star: The old thread mill that once held the Blue Mountain community together is finally unraveling. Earlier this month, the mill's present owner, Barbour Thread, announced it would lay off 214 of its employees in July, leaving only 110 jobs. Prospects for those lasting long are not good. The decline won't materially affect the town of Blue Mountain very much, as the mill removed itself from corporate limits years ago to avoid paying taxes to the town in which it was established.
Also on this date: The Alabama Senate this week approved legislation that creates an 11th seat on the ten-person Jacksonville State University board of trustees. The at-large position makes room for Alabama singer Randy Owen, who was recently appointed by Gov. Don Siegelman. The legislation also stipulates that once a former JSU trustee reaches the age of 70, he or she may be designated by the board as a trustee emeritus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Billions in Deals Reshaping the Cell and Gene Therapy Industry, reports Kalorama Information
ARLINGTON, Va., June 13, 2025 /PRNewswire/ -- Kalorama Information, a leading publisher of life sciences market research, has released the highly anticipated third edition of its landmark report, Cell and Gene Therapy Market Deals: Investments, M&As, and Partnerships, 2021–2025. This comprehensive analysis offers an in-depth look at the financial ecosystem fueling the explosive growth of the cell and gene therapy (CGT) industry — a market defined by breakthrough innovation, global competition, and evolving funding landscapes. The report is released in two installments, with the first part available now, covering deals through Q4 2024. The second installment, included with purchase, will be released in Fall 2025 and cover activity through Q3 2025. "Many categories of deals, such as collaborations, distribution/co-marketing, and manufacturing/supply chain, have shown a long-term pattern of growth," said Justin Saeks, senior market analyst at Kalorama Information. "And there's reason for optimism regarding continued investments. Cell and gene therapy-related companies have continued to receive huge amounts of investment." Key Insights from the Report: Over 2,000 CGT-related deals analyzed, with quarterly trends tracked from Q1 2021 to Q4 2024 Despite a tighter funding environment, 2024 investment reached an estimated $39 billion, with a sharp Q4 uptick Top dealmakers include Astellas, Bristol Myers Squibb, Ginkgo Bioworks, Charles River, and Eli Lilly Deal types covered: VC/PE, IPO/SPAC, licensing, tech transfer, acquisitions, supply chain partnerships, and more Global perspective includes detailed breakdowns by region — North America, Europe, and APAC Why This Matters Now The CGT market is maturing fast, with fluctuating investment trends, growing deal diversity, and strategic partnerships becoming essential to survival. In 2023 and 2024, firms faced a contraction in available capital — from $73 billion in 2021 down to $35 billion in 2023 — yet collaborative and manufacturing partnerships have been on the rise. This suggests that dealmaking is evolving, not disappearing. Who Should Purchase and Read This Report This report is essential for: Biotech and pharma execs seeking M&A or licensing opportunities VC/PE investors tracking funding cycles and active biotech targets Strategic planners and BD professionals looking to benchmark activity Consultants, CROs, and CMOs aligning services with market needs Regulatory and policy advisors assessing funding shifts and regional dynamics Strategic Use Cases Identify high-activity players and ideal partners for collaboration or acquisition Benchmark funding rounds and valuations for startups or expanding companies Inform R&D focus by tracking which technologies (e.g., CRISPR, AAV) are attracting deals Support global expansion using regional deal patterns and emerging market trends Strengthen regulatory preparedness by understanding the impact of policy shifts on financing Companion Report Available This report pairs with Kalorama's Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 2024–2030 (4th Edition) — offering disease-area breakdowns of the CGT landscape in oncology, neurology, musculoskeletal, and beyond. Get the Report Download or purchase the report here:Cell and Gene Therapy Market Deals: Investments, M&As, and Partnerships, 2021–2025 (3rd Edition) Explore the companion report:Cell and Gene Therapy Market Dynamics by Disease Type, 2024–2030 (4th Edition) About Kalorama InformationKalorama Information, part of Science and Medicine Group, is a trusted source of market research in the life sciences. With a focus on in vitro diagnostics, biotechnology, and medical devices, Kalorama reports are used by top healthcare companies, government agencies, and investment firms worldwide. For purchase or custom consultation, contact:Sheri DavieKalorama Information Sales For media inquiries please contact:Alisa AlvichMarketing View original content to download multimedia: SOURCE Kalorama Information Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Billions in Deals Reshaping the Cell and Gene Therapy Industry, reports Kalorama Information
ARLINGTON, Va., June 13, 2025 /PRNewswire/ -- Kalorama Information, a leading publisher of life sciences market research, has released the highly anticipated third edition of its landmark report, Cell and Gene Therapy Market Deals: Investments, M&As, and Partnerships, 2021–2025. This comprehensive analysis offers an in-depth look at the financial ecosystem fueling the explosive growth of the cell and gene therapy (CGT) industry — a market defined by breakthrough innovation, global competition, and evolving funding landscapes. The report is released in two installments, with the first part available now, covering deals through Q4 2024. The second installment, included with purchase, will be released in Fall 2025 and cover activity through Q3 2025. "Many categories of deals, such as collaborations, distribution/co-marketing, and manufacturing/supply chain, have shown a long-term pattern of growth," said Justin Saeks, senior market analyst at Kalorama Information. "And there's reason for optimism regarding continued investments. Cell and gene therapy-related companies have continued to receive huge amounts of investment." Key Insights from the Report: Over 2,000 CGT-related deals analyzed, with quarterly trends tracked from Q1 2021 to Q4 2024 Despite a tighter funding environment, 2024 investment reached an estimated $39 billion, with a sharp Q4 uptick Top dealmakers include Astellas, Bristol Myers Squibb, Ginkgo Bioworks, Charles River, and Eli Lilly Deal types covered: VC/PE, IPO/SPAC, licensing, tech transfer, acquisitions, supply chain partnerships, and more Global perspective includes detailed breakdowns by region — North America, Europe, and APAC Why This Matters Now The CGT market is maturing fast, with fluctuating investment trends, growing deal diversity, and strategic partnerships becoming essential to survival. In 2023 and 2024, firms faced a contraction in available capital — from $73 billion in 2021 down to $35 billion in 2023 — yet collaborative and manufacturing partnerships have been on the rise. This suggests that dealmaking is evolving, not disappearing. Who Should Purchase and Read This Report This report is essential for: Biotech and pharma execs seeking M&A or licensing opportunities VC/PE investors tracking funding cycles and active biotech targets Strategic planners and BD professionals looking to benchmark activity Consultants, CROs, and CMOs aligning services with market needs Regulatory and policy advisors assessing funding shifts and regional dynamics Strategic Use Cases Identify high-activity players and ideal partners for collaboration or acquisition Benchmark funding rounds and valuations for startups or expanding companies Inform R&D focus by tracking which technologies (e.g., CRISPR, AAV) are attracting deals Support global expansion using regional deal patterns and emerging market trends Strengthen regulatory preparedness by understanding the impact of policy shifts on financing Companion Report Available This report pairs with Kalorama's Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 2024–2030 (4th Edition) — offering disease-area breakdowns of the CGT landscape in oncology, neurology, musculoskeletal, and beyond. Get the Report Download or purchase the report here:Cell and Gene Therapy Market Deals: Investments, M&As, and Partnerships, 2021–2025 (3rd Edition) Explore the companion report:Cell and Gene Therapy Market Dynamics by Disease Type, 2024–2030 (4th Edition) About Kalorama InformationKalorama Information, part of Science and Medicine Group, is a trusted source of market research in the life sciences. With a focus on in vitro diagnostics, biotechnology, and medical devices, Kalorama reports are used by top healthcare companies, government agencies, and investment firms worldwide. For purchase or custom consultation, contact:Sheri DavieKalorama Information Sales For media inquiries please contact:Alisa AlvichMarketing View original content to download multimedia: SOURCE Kalorama Information Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
2 hours ago
- Associated Press
ROSEN, SKILLED INVESTOR COUNSEL, Encourages West Pharmaceutical Services, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action
New York, New York--(Newsfile Corp. - June 13, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of West Pharmaceutical Services, Inc. (NYSE: WST) between February 16, 2023 and February 12, 2025, both dates inclusive (the 'Class Period'), of the important July 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased West common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the West class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 7, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West was in fact experiencing significant and ongoing destocking across its high-margin High-Value Products ('HVP') portfolio; (2) West's SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to West's profit margins due to operational inefficiencies; (3) these margin pressures created the risk of costly restructuring activities, including West's exit from continuous glucose monitoring ('CGM') contracts with long-standing customers; and (4) as a result of the foregoing, defendants' positive statements about West's business, operations, and prospects were materially false and/or misleading or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the West class action, go to call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] To view the source version of this press release, please visit
